NCT06057402 2026-04-16
MagnetisMM15
Pfizer
Phase 4 Recruiting
Clinical Trials
9 trialsNCT07030517 2026-04-14
A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma
Johnson & Johnson Private Limited
Phase 4 Recruiting
NCT05201781 2026-04-13
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Janssen Research & Development, LLC
Phase 4 Recruiting
NCT07101445 2026-02-10
Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial
Emory University
Phase 4 Recruiting
NCT07094048 2026-01-07
CHUQUL_HO001
CHU de Quebec-Universite Laval
Phase 4 Recruiting
NCT05722405 2026-01-05
Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 4 Recruiting
NCT06251076 2025-12-10
Plan Development for Giving Teclistamab in the Outpatient Setting
University Health Network, Toronto
Phase 4 Recruiting
NCT07025005 2025-11-04
VRd MM Fibrate
Tanta University
Phase 4 Recruiting
NCT06409702 2025-06-12
Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
The First Affiliated Hospital of Soochow University
Phase 4 Recruiting